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Alveolar macrophage (AM) is a mononuclear phagocyte key to the defense against
respiratory infections. To understand AM’s role in airway disease development, we
examined the influence of Secretoglobin family 1a member 1 (SCGB1A1), a pulmonary
surfactant protein, on AM development and function. In a murine model, high-
throughput RNA-sequencing and gene expression analyses were performed on purified
AMs isolated from mice lacking in Scgb1a1 gene and were compared with that from
mice expressing the wild type Scgb1a1 at weaning (4 week), puberty (8 week), early
adult (12 week), and middle age (40 week). AMs from early adult mice under Scgb1a1
sufficiency demonstrated a total of 37 up-regulated biological pathways compared to
that at weaning, from which 30 were directly involved with antigen presentation, anti-
viral immunity and inflammation. Importantly, these pathways under Scgb1a1 deficiency
were significantly down-regulated compared to that in the age-matched Scgb1a1-
sufficient counterparts. Furthermore, AMs from Scgb1a1-deficient mice showed an early
activation of inflammatory pathways compared with that from Scgb1a1-sufficient mice.
Our in vitro experiments with AM culture established that exogenous supplementation
of SCGB1a1 protein significantly reduced AM responses to microbial stimuli where
SCGB1a1 was effective in blunting the release of cytokines and chemokines (including
IL-1b, IL-6, IL-8, MIP-1a, TNF-a, and MCP-1). Taken together, these findings suggest
an important role for Scgb1a1 in shaping the AM-mediated inflammation and immune
responses, and in mitigating cytokine surges in the lungs.
Keywords: club cell, alveolar macrophage, lung surfactant, SCGB1A1, Clara cell secretory protein, cytokine storm
INTRODUCTION
The ongoing pandemic of Coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has already affected over 30 million people
across the globe resulting in more than one million deaths (1, 2). It produces a significant amount
of severe illnesses that overwhelm health care infrastructure. Early studies have shown that the
prognosis of COVID-19 may be variable among different populations and age groups. Particularly,
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it disproportionately affects the elderly and patients with
preexisting conditions including chronic obstructive pulmonary
disease (COPD) and hypertension compared to any other
conditions (3, 4). Mechanisms of SARS-CoV-2 persistence
and pathogenicity remains largely unknown; however, its
widespread infection and associated fatalities outnumber the
past coronavirus outbreaks such as the Middle East respiratory
syndrome-related coronavirus and severe acute respiratory
syndrome-associated coronavirus. The rapid decline in lung
function and some of the COVID-19 patients requiring oxygen
support and/or mechanical ventilation has been attributed
to cytokine storm (5). There is no targeted anti-viral therapy
currently available for COVID-19 and efforts to develop vaccines
are ongoing. In this context, examining the cellular, and/or
molecular interactions within the lung microenvironment
may provide useful insights into the pathogenesis and
possible therapeutics of COVID-19 and other infectious
respiratory diseases.
Alveolar macrophages (AMs) are stationary cells of embryonic
origin that constitute greater than 95% of the phagocyte pool
in the alveolar space (6, 7). Consequently, AMs perform crucial
immune surveillance at the respiratory surface providing the first
line defense against airborne pathogens, pollutants (8–12), and
clearing of cellular debris (13). AMs function as professional
antigen presenting cells in eliciting antigen specific T cells and
antibodies targeting pathogens (14, 15) and autoantigens (16, 17).
AMs also can respond to various microbial stimuli producing
an array of cytokines and chemokines that may influence the
landscape of inflammation and immunologic outcomes (16–18).
On the other hand, club cells are a significant contributor
to the homeostatic and reparative processes in the lungs
(19). These non-ciliated and non-mucous-producing cells in
the bronchiolar epithelium can differentiate into pulmonary
epithelial and endothelial cells following tissue injury (20–
23), and via secreted secretoglobin family 1A member 1
(SCGB1A1) protein, a component of the pulmonary surfactant,
can exert anti-inflammatory and anti-fibrotic functions (24).
Specifically, SCGB1A1 binds and sequesters key inflammatory
mediators of airway diseases including prostaglandins (25,
26), phospholipase (PL) A2 (27–29) and PLC (28), and
inhibits activation and translocation of NF-κB (30, 31). Lung
infection by viruses and bacteria are known to elicit greater
inflammatory responses in the absence of SCGB1A1 (32–34),
whereas respiratory distress decreases SCGB1A1 levels following
acute lung injury (35); exposures to pollutants (36), cigarette
smoke (37) and ozone (38); lung allograft rejection (39–41);
respiratory infections (42, 43); and chronic lung diseases (44,
45). Overexpression of Scgb1a1 in airways has shown to limit
ventilator induced lung injury and inflammation (46), and
supplementation of exogenous SCGB1A1 has mitigated the
increased proinflammatory cytokines and inflammatory buildup
caused by Scgb1a1 germline-deficiency (24).
Because AMs are non-migratory cells that adhere to the
alveolar epithelium (47), they are constantly immersed in
pulmonary surfactant and are likely to be influenced by the
surfactant components. Under steady state, AMs exhibit a
non-inflammatory phenotype while SCGB1A1 occurs at its
physiologic maximum. Club cells, on the other hand, succumb
to respiratory distress resulting in decreased SCGB1A1 levels. As
the crosstalk between club cells and AMs is largely unknown,
for the first time in the present study, we examine the
transcriptomic profiles of mouse AMs during development and
compare the shift in gene expression under Scgb1a1-deficiency.
Furthermore, we also analyze the effects of SCGB1A1 protein on
purified AMs delineating therapeutic implications of SCGB1A1
in inflammatory and fibrotic lung diseases.
MATERIALS AND METHODS
Experimental Animals
Wild type (WT, Scgb1a1+/+) C57BL/6 mice were procured from
Charles River Laboratories and Uteroglobin gene knockout (KO)
mice (Scgb1a1−/−) (48) were obtained from National Institutes
of Health. Mice were housed at the Washington University
School of Medicine according to institutional guidelines and
approved protocols. Mice from WT and KO groups were
euthanized at 4, 8, 12, and 40 weeks of age [respectively,
equivalent to 6 months, 12 years, 20 years, and 40 years in human
age (49)] and relevant samples were collected for further study
(n = 3/group).
Flow Cytometry Analysis
We performed multicolor flow cytometry to analyze expression
of a panel of phenotypic and functional markers. Bronchoalveolar
lavage (BAL) cells were isolated per our established protocol (50)
and incubated with Fc block (BD Bioscience) to prevent non-
specific antibody binding. They were incubated with fluorophore
tagged antibodies for CD45, CD11c and Siglec-F, and were
analyzed with a BD LSR Fortessa cell analyzer (BD Bioscience).
The functional states of AM at 4, 8, 12, and 40 weeks were
compared between the KO and WT groups. Single stain control
and fluorescence minus one control were included in every study
and data were analyzed by FlowJo v10.6.2 (BD Life Sciences).
AM Isolation and RNA Purification
Alveolar macrophages, defined as CD45+, CD11chi, and Siglec-
Fhi granular cells, were isolated from BAL fluid via flow cytometry
cell sorting technique following our previous study (50), and
age-matched samples were collected and processed on the same
day to minimize batch-to-batch variation. AMs were isolated
individually from three mice per group and were sorted directly
into RNA Lysis buffer using a PureLink RNA kit (Thermo Fisher
Scientific). Total RNA was treated by DNase I (Thermo Fisher
Scientific), quantitated by Nanodrop (Thermo Fisher Scientific),
and stored at -80◦C.
RNA Sequencing and Bioinformatics
Analysis
Three biologic replicates per group were included to ensure
a strong statistical power for detecting the inter- and intra-
group variations. Total RNA (up to 100 pg) was subjected to
the picoRNA workflow (Cofactor Genomics). A poly-A library
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was constructed and 6 × 107 single-end reads were performed.
Following RIN score (>7) determination and enrichment for
mRNA, RNA sequencing was performed (Cofactor Genomics)
for 60 million single-end reads covering >75 base pairs/read.
RNA-seq reads were then aligned to the 76 primary assemblies
for Mus musculus with STAR version 2.5.1a. Gene counts were
derived from the number of uniquely aligned unambiguous
reads by Sub read: feature Count version 1.4.6-p5. All gene
counts were then imported into the R/Bioconductor package
EdgeR and TMM normalization size factors were calculated to
adjust for samples for differences in library size. The TMM size
factors and the matrix of counts were then imported into the
R/Bioconductor package Limma, and analyzed for differential
expression using Limma/voom and sequencing data was analyzed
by Genomics Suite (Partek). The data set has been submitted to
Gene Expression Omnibus (GEO) with accession no GSE148647.
The data were examined for changes in transcription profile in
comparison with their WT counterpart by three-dimensional
PCA plot, hierarchical clustering, Venn diagram, volcano plot,
and profile trellis and gene ontology enrichment. Generally
applicable gene set enrichment (GAGE) method was applied
for pathway analysis (51) through databases including gene
ontology (GO, molecular function and biological process) and
Kyoto encyclopedia of genes and genome (KEGG, metabolism
and disease pathway). The Benjamini and Hochberg’s False
Discovery Rate (FDR) correction was performed to determine the
significance of gene expression (51).
Influence of SCGB1a1 Protein on AM
Response to Inflammatory Stimuli
The effect of SCGB1a1 protein on AM responsiveness to
inflammatory stimuli were studied in vitro. Flow sorted AMs
were plated (50) in 12-well plates at 1 × 105 cells/well
in triplicates and were incubated with Toll-like receptor
(TLR) agonists (Invivogen) 2- heat-killed Listeria monocytogenes
(HKLM), TLR4-Lipopolysaccharide from Escherichia coli K12
(LPS) and TLR5- Salmonella typhimurium Flagellin (FLA) in
presence or absence of recombinant SCGB1a1 protein at 5 µg/mL
(Creative BioMart). Culture supernatant was collected and total
RNA was isolated at 72 h post-stimulation. The release of
FIGURE 1 | Influence of Secretoglobin family 1A member 1 (Scgb1a1) deficiency on alveolar macrophage (AM) phenotypes. (A) Flow cytometric analysis of mouse
AMs (CD45+, CD11chi, and Siglec-Fhi cells) from bronchoalveolar lavage fluid. (B) AMs from WT (Scgb1a1+/+) and KO (Scgb1a1−/−) mice were analyzed for
phenotypic differences at 4, 8, 12, and 40 weeks of age.
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FIGURE 2 | Gene expression in AMs from wild type mice across age groups. (A) Up-regulated and down-regulated genes in AMs at 4, 8, 12, and 40 weeks; (B–D)
Volcano plots of significantly up-regulated (red) and down-regulated (blue) genes (FDR < 0.05); (E) Venn diagrams of the significantly changed genes; Venn diagrams
of the significantly changed gene sets in AMs of the WT mice at different ages including GO-Molecular function pathways (F), GO-Biological process pathways (G),
KEGG-metabolism pathways (H), and KEGG-Disease pathways (I). FDR < 0.05 was considered significant; FC, fold change.
cytokines and chemokines in culture supernatant was analyzed by
a Bio-Plex 200 system (Bio-Rad) using multiplex immunoassays.
RESULTS
Influence of Scgb1a1 Deficiency on AM
Phenotype
We evaluated the prevalence and phenotype of AMs in age,
gender and strain matched Scgb1a1−/− and Scgb1a1+/+ mice.
AMs, identified as BAL cell leukocytes with expression of
CD11chi and Siglec-Fhi, were nearly identical between the KO
and WT groups at earlier time points of 4 and 8 weeks (Figure 1).
Interestingly, as early as 12-week, a unique population, albeit
minor, with CD11chi and Siglec-Flow began to appear in the
KO only. By 40-week, this population in KO had grown to
represent ∼7% cells compared to ∼1% of that in the age-
matched WT. Developmental origin and physiologic significance
of the CD11chi and Siglec-Flow cells in Scgb1a1−/− is currently
unknown; however, some unrelated studies have suggested a
monocytic precursor for the Siglec-Flow pulmonary macrophages
(52, 53). This phenotypic difference in AMs as early as 12 weeks of
age suggests a variation in myelopoiesis and/or activation status
associated with Scgb1a1 deficiency.
Genes and Gene Sets Differentially
Expressed in WT AMs
To study alteration in gene expression due to aging, we compared
the AM expressed genes at 8, 12, and 40 weeks with that at 4 weeks
in WT mice (Figure 2A). As shown in Figures 2B–D, there were
2312 genes at 8-week, 3135 genes at 12-week, and 872 genes at
40-week significantly up-regulated compared to that at the 4-
week (FDR ≤ 0.05). The overlapping pattern of gene expression
was categorized in a Venn diagram indicating that 656 genes
were remarkably altered at all time-points beyond 4 weeks of
age (Figure 2E). Additionally, ten most significantly up-regulated
and down-regulated genes along with FDR values are presented
in Supplementary Table 1.
To delineate the biological significance of the shift observed
in gene expression, we analyzed the significantly changed gene
sets using GAGE method and screened through GO and KEGG
databases (Figures 2F–I). As shown in Supplementary Table 2,
there were seven and three up-regulated GO molecular function
pathways at 8 and 12 weeks, respectively, in comparison to
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FIGURE 3 | Gene expression in AMs from Scgb1a1 KO mice across age groups. (A) Up-regulated and down-regulated genes in AMs at 4, 8, 12, and 40 weeks;
(B–D) Volcano plots of significantly up-regulated (red) and down-regulated (blue) genes (FDR < 0.05); (E) Venn diagrams of the significantly changed genes. Venn
diagrams of the significantly changed gene sets in AMs from KO mice at different ages including GO-Molecular function pathways (F), GO-Biological process
pathways (G), KEGG-metabolism pathways (H), and KEGG-Disease pathways (I). FDR < 0.05 was considered significant; FC, fold change.
that at 4 weeks. In contrast, the ribosome related pathway
was down-regulated at 8, 12, and 40 weeks compared to
that at 4 weeks. Importantly, most of the GO biological
processes including the innate immune response pathway
were up-regulated at 12-week compared with that at 4-week.
There were 37 significantly up-regulated biological processes
evident at 12-week, among which 30 biological pathways were
directly involved with immune defenses and inflammatory
process. No significant change in GO biological process was,
however, found at 40-week compared to that at 4-week. In the
KEGG metabolism pathway analysis, antigen processing and
presentation, phagosome, and cell adhesion molecule pathways
were significantly up-regulated at 8, 12, and 40 weeks than
that at 4 weeks. In the KEGG disease pathway analysis,
several infectious diseases and immune/metabolism related
pathways including that of Influenza A, Epstein-Barr virus
(EBV), Measles and Staphylococcus aureus, and non-alcoholic
liver disease were significantly changed at 8, 12, and 40 weeks
than that at 4 weeks.
In summary, most of the pathways for immunologic and
inflammatory responses were activated by 12 weeks of age.
This suggests that early adult WT mice may have a more
pronounced immunological defense compared to any other
age groups studied.
Significant Changes in Gene Expression
in KO AMs
To assess the patterns of AM gene expression due to aging under
Scgb1a1 deficiency, we studied flow-sorted AMs isolated from KO
mice (Figure 3A). Compared to gene expression at 4 weeks, there
were 671 genes at 8-week, 938 genes at 12-week, and 1344 genes
at 40-week that were significantly up-regulated (Figures 3B–D,
FDR≤ 0.05). The Venn diagram indicated that expression of 153
genes was remarkably altered at all time-points in comparison
to that at 4-week (Figure 3E). The ten most significantly up-
regulated and down-regulated genes along with FDR values are
presented in Supplementary Table 3.
To explore the biomedical significance of KO expressed
genes, we analyzed the pathways by using GAGE method and
screening through GO and KEGG databases (Figures 3F–I).
Interestingly, there was no significant change in GO molecular
function pathway among the KO age groups (Supplementary
Table 4). On the other hand, 18 and 6 GO biological processes
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FIGURE 4 | Comparison of the AM gene expression patterns in Scgb1a1 KO and WT mice. (A) Up-regulated and down-regulated genes in AMs at 4, 8, 12, and
40 weeks; (B–E). Volcano plots of significantly up-regulated (red) and down-regulated (blue) genes (FDR < 0.05); (F) PCA plot of the variant feature of gene
expression; (G) Venn diagrams of the significantly changed genes. Venn diagrams of the significantly changed gene sets in AMs from KO vs WT mice at different
ages including GO-Molecular function pathways (H), GO-Biological process pathways (I), KEGG-metabolism pathways (J), and KEGG-Disease pathways (K).
FDR < 0.05 was considered significant; FC, fold change.
were significantly up-regulated at 8 and 12 weeks of age,
respectively, compared to that at 4 weeks. At 40-week, no
significant change was, however, found in GO biological process.
In the KEGG metabolism pathway analysis, antigen processing
and presentation, and cell adhesion molecule pathways were
significantly up-regulated at 8-week and 12-week than that at 4-
week. In the KEGG disease pathway analysis, several infectious
disease-related pathways including that of Influenza A, EBV, viral
myocarditis, tuberculosis, and Herpes simplex virus (HSV) were
found significantly up-regulated at 8, 12, and 40 weeks of age.
In brief, most of the pathways for immunologic and
inflammatory responses were activated by 8 weeks and these
pathways were less pronounced than that in the WT mice,
suggesting an early onset of inflammation in KO mice.
Differential Expression of Genes and
Gene Sets in KO and WT AMs
To evaluate the effect of Scgb1a1 deficiency on AM transcriptome,
we compared the gene expression patterns between KO and WT
across the age groups (Figure 4A). As shown in Figures 4B–E,
4 genes at 4-week, 55 genes at 8-week, 1913 genes at 12-week,
and 616 genes at 40-week were significantly altered in the KO
AMs. The PCA plot showed gene expression patterns over time
in the KO and WT mice (Figure 4F). The overlap between these
genes was summarized in Figure 4G showing that the mice at 12-
week had the most significant changes in gene expression. It was
further presented in a Venn diagram indicating that 656 genes
were remarkably altered at all time-points compared to that at 4-
week (Figure 4G). The ten most significantly up-regulated and
down-regulated genes are presented in Supplementary Table 5.
To decipher biologic relevance of gene expression patterns,
we analyzed the significantly changed gene sets by using
GAGE method and screened through GO and KEGG databases
(Figures 4H–K). As shown in Supplementary Table 6, Ribosome
was the only one GO molecular function pathway that was
significantly down-regulated in 4-week old KO mice compared to
that in WT. In addition to Ribosome pathway, there were three
GO molecular function pathways that were down-regulated in
the KO mice at 8 weeks of age. Surprisingly, 17 GO biological
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FIGURE 5 | SCGB1A1 attenuates AM-mediated inflammation. Cytokine and chemokine release from purified C57BL/6 AMs in response to toll-like receptor (TLR)
agonists were measured: TLR2- heat-killed Listeria monocytogenes (HKLM), TLR4-Lipopolysaccharide from Escherichia coli K12 (LPS), and TLR5- Salmonella
typhimurium Flagellin (FLA) in the presence or absence of recombinant SCGB1a1 protein. The panels depict IL-1b (A), IL-6 (B), IL-8 (C), MIP1a (D), TNF-α (E), and
MCP1 (F) responses to TLR stimuli. Data from three biological replicates are plotted as mean ± SEM, two-tailed unpaired t-tests were applied, and p < 0.05 was
considered significant (*).
processes that are related to immune response or inflammation
were significantly down-regulated in the KO at 12-week. From
analysis of KEGG metabolism pathways, the antigen processing
and presentation, proteasome, TNF signaling, and NOD-like
receptor signaling were also significantly down-regulated in KO
at 12-week. In KEGG disease pathway analysis, several infectious
disease and immune related pathways including that of Influenza
A, EBV, HCV, and HSV were significantly down-regulated
whereas the non-alcoholic liver disease was significantly up-
regulated at 12-week in the KO mice.
In sum, pathways for immunologic and inflammatory
responses were less pronounced in KO AMs suggesting that
Scgb1a1 deficiency may undermine the repertoire of immune
defenses available to this age group.
Attenuation of AM-Mediated
Inflammation by SCGB1A1
We measured the cytokines and chemokines including
interleukin (IL)-1β, IL-6, IL-8, MIP-1α, tumor necrosis
factor (TNF)-α, and MCP-1 released by the flow-sorted
AMs from C57BL/6 mice in response to TLR agonists:
TLR2- heat-killed Listeria monocytogenes (HKLM), TLR4-
Lipopolysaccharide from Escherichia coli K12 (LPS) and
TLR5- Salmonella typhimurium Flagellin (FLA) in presence
or absence of recombinant SCGB1a1 protein. As shown in
Figure 5A, there was no significant change in the IL-1β
level in the SCGB1a1 treated AMs (0.233 ± 0.033 pg/mL)
than that in the untreated AMs (0.167 ± 0.120 pg/mL).
However, the IL-1β release by AM was strikingly high
when AMs were stimulated by LPS (52.660 ± 1.719 pg/mL,
p < 0.001), HKLM (20.613 ± 2.426 pg/mL, p = 0.001),
or FLA (27.707 ± 1.304 pg/mL, p < 0.001) than that
in the untreated group. Moreover, the TLR stimulated
cytokine/chemokine release was significantly reduced
by supplementation of SCGB1a1. The IL-1β levels in
LPS + SCGB1a1 (31.490 ± 1.588 pg/mL, p < 0.001),
HKLM + SCGB1a1 (10.673 ± 0.876 pg/mL, p = 0.001), or
FLA + SCGB1a1 (17.347 ± 1.130 pg/mL, p = 0.001) treated
AMs were significantly lower than that the LPS, HKLM, or FLA
only treated AMs. Furthermore, the administration of SCGB1a1
consistently lowered IL-6, IL-8, MIP-1α, TNF-α, and MCP-1
release from TLR induced AMs (Figures 5B–F). These data
indicated that SCGB1a1 protein supplementation reduced the
cytokine release induced by various microbial stimuli.
DISCUSSION
Alveolar macrophages are long-lived lung-resident phagocytes
that occur in the alveoli up to 6 × 109 cells per healthy human
adult (54) and are known to persist multitudes of infection,
inflammation and autoimmune conditions. While contribution
of AMs in eliciting pathogen and self-antigen specific immune
responses (14–17) have been well recognized, their role in
the inflammatory complications has not been fully understood.
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FIGURE 6 | Schematic representation of SCGB1A1 in AM-mediated inflammation and immunity.
To investigate potential anomalies in AM development and
function in the absence of SCGB1A1 protein, we studied the
phenotypes of AMs in age and gender matched Scgb1a1−/− and
Scgb1a1+/+ mice. While vast majority (>90%) of AMs were
identified as CD11chi and Siglec-Fhi leukocytes in BAL cells, a
minor population exhibited a phenotypic variation to be CD11chi
and Siglec-Flow consisting of 6.85% in the KO compared to
0.96% that in the WT. Developmental origin and pathogenic
significance of the CD11chi and Siglec-Flow cells in Scgb1a1−/−
are currently unknown; however, some unrelated studies have
suggested inflammatory monocytes as precursor for the Siglec-
Flow pulmonary macrophages (52, 53). This phenotypic difference
in AMs as early as 12 weeks of age (early adult) suggests a
variation in the myelopoiesis and/or activation status associated
with Scgb1a1 deficiency. Furthermore, purified AMs from WT
and Scgb1a1−/− KO mice were studied by RNA sequencing to
capture their transcriptome profiles in a time dependent manner.
Our study reveals a progressive AM transcriptome from
the Scgb1a1 WT mice at weaning (4 week), puberty (8 week),
early adult (12 week), and middle age (40 week) whereas
that in Scgb1a1 deficiency resembles the disorder of SCGB1A1
depletion induced by smoking, COPD and other types acute and
chronic lung injuries in the humans. Specifically, in the WT
mice, we found that the biological process pathways involving
antigen presentation, innate immune and anti-viral defenses were
significantly up-regulated at puberty, early adult, and middle age
than that at weaning. Strikingly, WT mice at the early adult age
had the most up-regulated immunological pathways suggesting
that this age group can harness higher anti-viral immunity
mediated by AMs. Although an increase in these processes was
observed in the KO mice with most activated pathways found
at puberty that further declined at early adult age and beyond,
this indicated a premature and weakened immune system in the
KO mice. These immunological changes between the KO and
WT mice were also observed when analyzed by an age-paired
comparison where the KO mice, at early adult age, had the most
compromised immune system than that in the WT mice. These
dynamic changes in anti-viral immunity during AM development
may have a clinical relevance on the varied outcomes of COVID-
19 among stratified age groups.
Both of the SARS-COV causing SARS (55) and SARS-COV-
2 causing COVID-19 (56) are known to utilize angiotensin-
converting enzyme 2 (ACE2) as a cell attachment receptor and
entry site. Hence, the tissue distribution of ACE2 and its dynamic
expression are crucial to understand the pathophysiology of
coronavirus infection. It has been shown that ACE2 is expressed
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in numerous tissues, including epithelial cells of the lung,
intestine, kidney and blood vessels (56). Within the lung, the
ACE2 is heavily expressed on alveolar type (AT) II cells (57–
59) and it is also found on the SCGB1A1-producing club cells
(60) that make these cell types vulnerable to the coronavirus
infection. This is particularly important since COVID-19 is
an airborne disease and SARS-COV-2 can travel through the
inhaled air to the permissive sites of infection in respiratory
bronchioles and alveoli. It is also concerning that smoking up-
regulates ACE2 expression in lungs (61) and a recent study
found current smokers to be 120% more likely to die from
SARS-COV-2 infection than non-smokers (4). The human
AMs are also susceptible to a strain of coronavirus infection
(62). Together, these findings highlight the importance of
AMs and club cells in the possible entry and transmission
of coronaviruses.
Anti-inflammatory effector function of SCGB1A1 has
been well studied and it has been shown that viral and
bacterial infections of lungs deficient in Scgb1a1 elicit greater
inflammatory responses. The pro-inflammatory cytokine
concentration and BAL cell count were significantly higher
in Scgb1a1-deficient lungs following an acute Adenovirus
infection (34). Similarly, infection by Respiratory syncytial virus
led to increased T-helper 2 cytokines, neutrophil chemokines
and viral replication following Scgb1a1 deficiency whereas
restoration of Scgb1a1 expression in the airway abrogated
the viral persistence and lung inflammation (33). It has been
reported that club cells from mouse airways can modulate
cytokine production by macrophages in the lung periphery
(63). Another in vitro study also found that supplementation
of exogenous SCGB1a1 can reverse cigarette smoke-induced
IL-8 release and attenuate airway inflammation in biopsy
specimens from patients with COPD (64). Currently, COVID-
19 is treated with supportive care and respiratory failure
from acute respiratory distress syndrome is the leading
cause of death (65). Accumulating evidence suggests that
a subgroup of patients with severe COVID-19 might have
cytokine storm syndrome (5) indicating an urgent need
for additional intervention and/or prophylaxis beyond
supportive care. In the present study, we found exogenous
supplementation of SCGB1a1 protein significantly blunted
AM release of cytokine storm syndrome mediators including
IL-6, IL-1β, TNF-α, IL-8, MIP-1α, and MCP-1. Moreover,
AMs are critical in eliciting anti-coronavirus CD4+ T cells
that remain important in mounting a specific and lasting
immune defense (66). Cytokine storm is believed to dampen
AM’s antigen presentation ability and cytokine neutralization
results in a greater frequency of anti-viral T cells. Therefore,
implementation of an early curb on AM inflammation and
cytokine surge may produce better outcome measures in
managing COVID-19 with lower mortality and higher virus
specific immunity.
Although findings from this study are interesting and likely
to have a high clinical relevance, there are several limitations
in the study. For instance, the study did not assess bi-
directional interactions between AMs and club cells, and their
influence on lung tissue repair, remodeling, and regeneration.
Such crosstalk may provide important insights into pulmonary
health and serve as early indicators of AM activation and/or
club cell damage under physiologic and pathologic conditions.
Additionally, we did not evaluate the association of SCGB1A1
concentration with ACE2 expression in AT II cells. Due
to current non-availability of humanized ACE2 transgenic
mouse model, we were unable to perform in vivo infection
studies with SARS-CoV-2 in the setting of Scgb1a1 deficiency.
In sum, SCGB1A1 influenced AM functionality where AMs
developing under Scgb1a1 deficiency showed a diminished
ability to stimulate adaptive immune responses. Given the high
density of AMs in lung tissue, exogenous supplementation
of SCGB1A1 may be helpful to restore AM SteadyState
functions and prevent local cytokine surges in infectious and
autoimmune diseases (Figure 6).
CONCLUSION
Although AMs and lung surfactants have been widely studied,
their respective roles have been analyzed more in isolation than
in tandem. To our knowledge, this is the first investigation
that establishes a functional link between these two entities
where Scgb1a1, a constituent of the lung surfactant, regulates
AM development, gene transcription, and responsiveness to
inflammation. In general, AMs developing under Scgb1a1-
deficiency were skewed toward an inflammatory phenotype,
whereas exogenous supplementation of recombinant SCGB1A1
protein exhibited anti-inflammatory effects on AM activation.
While it is imperative to maintain physiologic levels of
SCGB1A1 in the lung milieu for an optimal SteadyState
respiration, we speculate that a lung locale overexpression of
Scgb1a1 via gene therapy or an airway delivery of recombinant
protein might be helpful in curbing lung inflammation and
cytokine surge in the management of COVID-19 and other
inflammatory lung diseases.
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